ASCO 2025 | IGNYTE-3: vusolimogene oderparepvec and nivolumab in cutaneous melanoma
Jason Luke, MD, FACP, FASCO, University of Pittsburgh, Pittsburgh, PA, discusses the Phase III IGNYTE-3 trial (NCT06264180) of vusolimogene oderparepvec (RP1), an oncolytic viral therapy, plus nivolumab versus physician’s choice in patients with advanced cutaneous melanoma that has progressed following anti–PD-1 and anti–CTLA-4 therapy. This trial aims to assess overall survival as the primary endpoint, with secondary endpoints including progression-free survival and objective response rate. The study addresses a significant unmet need for effective therapies in this heavily pretreated melanoma population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
